beauvericin has been researched along with Osteogenic Sarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Cheng, M; Deng, L; He, Y; Huang, M; Jiao, Y; Li, Y; Ouyang, J; Qi, Q; Song, X; Tu, Z; Wang, C; Wang, L; Wang, S; Wang, Z; Ye, G; Ye, W; Zhang, D; Zhang, J | 1 |
1 other study(ies) available for beauvericin and Osteogenic Sarcoma
| Article | Year |
|---|---|
Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway.
Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Osteosarcoma; Receptor, Transforming Growth Factor-beta Type II | 2023 |